HEGLN acquires assets of Canada's Urodynamix
Shanghai. November 12. INTERFAX-CHINA - HEGLN (Dalian) Pharmaceutical Co. Ltd. has signed an agreement to purchase all assets and technologies owned by Canada's Urodynamix Technologies Ltd., HEGLN announced on its Web site Nov. 11.
Urodynamix is a medical device company which develops and commercializes non-invasive bladder monitor systems that use near-infrared spectroscopy (NIRS) technology.
The Canadian company's main product is the UroNIRS 2000, a bladder monitor system that provides real-time and non-invasive evaluation of bladder function during voiding to aid in the diagnosis of bladder outlet obstruction.
According to the announcement, the UroNIRS 2000 has been marketed in the United States, Canada, the Netherlands and South Korea.
"There is currently no such medical device available in China, and HEGLN plans to introduce the product to the domestic market soon," a HEGLN employee surnamed Zhang told Interfax Nov. 12.
The deal is worth more than $2 million, according to Zhang,